FDA fast tracks Mesoblast COVID-19 treatment

FDA fast tracks Mesoblast COVID-19 treatment

A COVID-19 treatment being developed by Australian pharmaceutical company Mesoblast (ASX: MSB) has been granted Fast Track designation by the US Food and Drug Administration (FDA) today.

The designation is for MSB's treatment of acute respiratory distress syndrome (ARDs) - a potentially fatal complication of COVID-19 infection called remestemcel-L.

As a result, the FDA will assist in the development of remestemcel-L and will expedite the review of the drug because it fills an unmet medical need.

Under Fast Track designation, a Biologic License Application (BLA) for remestemcel-L is eligible for both rolling submission and priority review.

In its submission to the FDA Mesoblast highlighted results from a pilot study of remestemcel-L under emergency compassionate use at New York's Mt Sinai Hospital in March-April this year.

In this study, nine of 12 ventilator-dependent patients with moderate to severe COVID-19 ARDS were successfully discharged from hospital a median of 10 days after receiving two intravenous doses of remestemcel-L.

An ongoing Phase 3 trial of the drug in up to 300 ventilator-dependent patients is approximately two thirds enrolled.

Two interim analyses of this trial have been performed by the independent Data Safety Monitoring Board (DSMB), with recommendations to continue the trial.

Receipt of the Fast Track designation comes after Mesoblast entered into a license and collaboration agreement with Novartis for the development, manufacture and commercialisation of remestemcel-L.

As part of the deal Switzerland-based Novartis will make a US$50 million (AUD$68.7 million) upfront payment to Mesoblast.

Following the initiation of a Phase 3 clinical trial, Novartis will fully fund the global clinical development of the drug.

In addition, Mesoblast may receive a total of US$505 million (AUD$694 million) pending achievement of pre-commercialisation milestones for remestemcel-L and a further US$750 million (AUD$1 billion) based on achieving certain sales milestones.

Mesoblast will retain full rights for the use of remestemcel-L for treatment of graft versus host disease.

Updated at 9.58am AEDT on 2 December 2020.

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

Former IPO hopeful Limepay acquired by Spenda at a fraction of the $43.5m invested

Former IPO hopeful Limepay acquired by Spenda at a fraction of the $43.5m invested

White-label buy-now pay-later (BNPL) company Limepay may have ...

Melbourne construction safety software group HammerTech receives $105m investment for growth

Melbourne construction safety software group HammerTech receives $105m investment for growth

HammerTech, a Melbourne-headquartered safety intelligence software ...

Here’s how to make sure Indigenous businesses keep thriving across a wide range of industries

Here’s how to make sure Indigenous businesses keep thriving across a wide range of industries

When discussing the creativity and ingenuity of Indigenous people, ...

Lifestyle Communities denies allegations after ABC exposé over exit fees, targeting “Miss Lonely”

Lifestyle Communities denies allegations after ABC exposé over exit fees, targeting “Miss Lonely”

Land lease company Lifestyle Communities (ASX: LIC) has denied alle...